Sukhi Jagpal
Nessuna posizione attualmente
Storia della carriera di Sukhi Jagpal
Precedenti posizioni note di Sukhi Jagpal
Società | Posizione | Inizio | Fine |
---|---|---|---|
SIERRA ONCOLOGY, INC. | Direttore Finanziario/CFO | 01/02/2015 | 01/07/2022 |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | Comptroller/Controller/Auditor | 01/03/2003 | 06/03/2013 |
Direttore Finanziario/CFO | 10/07/2012 | 26/01/2015 |
Formazione di Sukhi Jagpal
Queen's University | Masters Business Admin |
Johnson Graduate School of Management | Masters Business Admin |
Statistiche
Distribuzione geografica
Canada | 4 |
Stati Uniti | 2 |
Posizioni
Masters Business Admin | 2 |
Director of Finance/CFO | 2 |
Comptroller/Controller/Auditor | 1 |
Settori
Consumer Services | 3 |
Commercial Services | 2 |
Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 2 |
---|---|
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | Commercial Services |
Sierra Oncology, Inc.
Sierra Oncology, Inc. BiotechnologyHealth Technology Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA. | Health Technology |
- Borsa valori
- Insiders
- Sukhi Jagpal
- Esperienza